Literature DB >> 28511572

mTOR drives cerebral blood flow and memory deficits in LDLR-/- mice modeling atherosclerosis and vascular cognitive impairment.

Jordan B Jahrling1, Ai-Ling Lin2, Nicholas DeRosa1, Stacy A Hussong1, Candice E Van Skike1, Milena Girotti3, Martin Javors4, Qingwei Zhao5, Leigh Ann Maslin6, Reto Asmis6,7, Veronica Galvan1.   

Abstract

We recently showed that mTOR attenuation blocks progression and abrogates established cognitive deficits in Alzheimer's disease (AD) mouse models. These outcomes were associated with the restoration of cerebral blood flow (CBF) and brain vascular density (BVD) resulting from relief of mTOR inhibition of NO release. Recent reports suggested a role of mTOR in atherosclerosis. Because mTOR drives aging and vascular dysfunction is a universal feature of aging, we hypothesized that mTOR may contribute to brain vascular and cognitive dysfunction associated with atherosclerosis. We measured CBF, BVD, cognitive function, markers of inflammation, and parameters of cardiovascular disease in LDLR-/- mice fed maintenance or high-fat diet ± rapamycin. Cardiovascular pathologies were proportional to severity of brain vascular dysfunction. Aortic atheromas were reduced, CBF and BVD were restored, and cognitive dysfunction was attenuated potentially through reduction in systemic and brain inflammation following chronic mTOR attenuation. Our studies suggest that mTOR regulates vascular integrity and function and that mTOR attenuation may restore neurovascular function and cardiovascular health. Together with our previous studies in AD models, our data suggest mTOR-driven vascular damage may be a mechanism shared by age-associated neurological diseases. Therefore, mTOR attenuation may have promise for treatment of cognitive impairment in atherosclerosis.

Entities:  

Keywords:  Atherosclerosis; cerebral blood flow; cognition; inflammation; vascular biology

Mesh:

Substances:

Year:  2017        PMID: 28511572      PMCID: PMC5757441          DOI: 10.1177/0271678X17705973

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  74 in total

Review 1.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 2.  Cardiovascular risk factors and Alzheimer's disease.

Authors:  José A Luchsinger; Richard Mayeux
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

3.  Positive correlation between elevated plasma cholesterol levels and cognitive impairments in LDL receptor knockout mice: relevance of cortico-cerebral mitochondrial dysfunction and oxidative stress.

Authors:  J de Oliveira; M A Hort; E L G Moreira; V Glaser; R M Ribeiro-do-Valle; R D Prediger; M Farina; A Latini; A F de Bem
Journal:  Neuroscience       Date:  2011-09-16       Impact factor: 3.590

Review 4.  Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.

Authors:  Andras Perl
Journal:  Nat Rev Rheumatol       Date:  2015-12-24       Impact factor: 20.543

5.  The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes.

Authors:  Nicholas F Brown; Maja Stefanovic-Racic; Ian J Sipula; German Perdomo
Journal:  Metabolism       Date:  2007-11       Impact factor: 8.694

6.  Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Authors:  Vanessa P Houde; Sophie Brûlé; William T Festuccia; Pierre-Gilles Blanchard; Kerstin Bellmann; Yves Deshaies; André Marette
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

7.  Duration of rapamycin treatment has differential effects on metabolism in mice.

Authors:  Yimin Fang; Reyhan Westbrook; Cristal Hill; Ravneet K Boparai; Oge Arum; Adam Spong; Feiya Wang; Martin A Javors; Jie Chen; Liou Y Sun; Andrzej Bartke
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

8.  Rapamycin extends life and health in C57BL/6 mice.

Authors:  Yiqiang Zhang; Alex Bokov; John Gelfond; Vanessa Soto; Yuji Ikeno; Gene Hubbard; Vivian Diaz; Lauren Sloane; Keith Maslin; Stephen Treaster; Samantha Réndon; Holly van Remmen; Walter Ward; Martin Javors; Arlan Richardson; Steven N Austad; Kathleen Fischer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-16       Impact factor: 6.053

Review 9.  Metabolic complications with the use of mTOR inhibitors for cancer therapy.

Authors:  Shanthi Sivendran; Neeraj Agarwal; Benjamin Gartrell; Jian Ying; Kenneth M Boucher; Toni K Choueiri; Guru Sonpavde; William K Oh; Matthew D Galsky
Journal:  Cancer Treat Rev       Date:  2013-05-16       Impact factor: 12.111

10.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

View more
  15 in total

Review 1.  Role of age-related alterations of the cerebral venous circulation in the pathogenesis of vascular cognitive impairment.

Authors:  Gabor A Fulop; Stefano Tarantini; Andriy Yabluchanskiy; Andrea Molnar; Calin I Prodan; Tamas Kiss; Tamas Csipo; Agnes Lipecz; Priya Balasubramanian; Eszter Farkas; Peter Toth; Farzaneh Sorond; Anna Csiszar; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-08       Impact factor: 4.733

2.  mTOR Attenuation with Rapamycin Reverses Neurovascular Uncoupling and Memory Deficits in Mice Modeling Alzheimer's Disease.

Authors:  Candice E Van Skike; Stacy A Hussong; Stephen F Hernandez; Andy Q Banh; Nicholas DeRosa; Veronica Galvan
Journal:  J Neurosci       Date:  2021-04-22       Impact factor: 6.167

Review 3.  Mechanisms of Vascular Aging.

Authors:  Zoltan Ungvari; Stefano Tarantini; Anthony J Donato; Veronica Galvan; Anna Csiszar
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

4.  Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment.

Authors:  Candice E Van Skike; Jordan B Jahrling; Angela B Olson; Naomi L Sayre; Stacy A Hussong; Zoltan Ungvari; James D Lechleiter; Veronica Galvan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

Review 5.  A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review.

Authors:  Candice E Van Skike; Veronica Galvan
Journal:  Gerontology       Date:  2018-01-11       Impact factor: 5.140

Review 6.  Rapamycin in ischemic stroke: Old drug, new tricks?

Authors:  Gina Hadley; Daniel J Beard; Yvonne Couch; Ain A Neuhaus; Bryan A Adriaanse; Gabriele C DeLuca; Brad A Sutherland; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2018-10-18       Impact factor: 6.200

Review 7.  Effect of rapamycin on aging and age-related diseases-past and future.

Authors:  Ramasamy Selvarani; Sabira Mohammed; Arlan Richardson
Journal:  Geroscience       Date:  2020-10-10       Impact factor: 7.713

8.  Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice.

Authors:  Sarbani Ghoshal; Subhashis Banerjee; Jinsong Zhang; Michael L Niehoff; Susan A Farr; Andrew A Butler
Journal:  Peptides       Date:  2021-10-22       Impact factor: 3.750

9.  Folic acid delays development of atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Sunlei Pan; Huahua Liu; Feidan Gao; Hangqi Luo; Hui Lin; Liping Meng; Chengjian Jiang; Yan Guo; Jufang Chi; Hangyuan Guo
Journal:  J Cell Mol Med       Date:  2018-03-23       Impact factor: 5.310

10.  Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review.

Authors:  Daniel S Heard; Camilla S L Tuttle; Nicola T Lautenschlager; Andrea B Maier
Journal:  Front Physiol       Date:  2018-10-30       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.